[Form 4] CG Oncology, Inc. Common stock Insider Trading Activity

Rhea-AI Filing Summary

Leonard E. Post, a director of CG Oncology, Inc. (CGON), reported transactions on Form 4 dated 09/04/2025 reflecting activity on 09/03/2025. The filing shows purchase and sale activity plus option holdings. Mr. Post acquired 1,000 shares of common stock at $0.60 per share and simultaneously sold 1,000 shares under a Rule 10b5-1 plan at $28.00 per share. The director holds a fully vested stock option exercisable at $0.60 covering 1,000 shares and, following the reported transactions, beneficially owns 125,077 shares directly. The sale was executed pursuant to a 10b5-1 trading plan adopted on September 6, 2024.

Positive

• Sale executed under a Rule 10b5-1 plan, indicating a pre-established trading arrangement intended to provide compliance with insider trading rules
• Director holds fully vested option (1,000-share option exercisable at $0.60), demonstrating alignment with equity compensation practices
• Form 4 properly signed and filed by attorney-in-fact, indicating procedural compliance with reporting requirements

Negative

• Director sold 1,000 shares at $28.00, which is an outward disposition of insider-held shares (size and company impact not provided in this filing)
• Purchase and sale occurred same day, which may prompt investor questions even though the sale was under a 10b5-1 plan

Insights

Financial Analyst

TL;DR: Director executed offsetting buy and sale and holds a fully vested option; transactions appear routine and plan-driven.

The Form 4 discloses a contemporaneous small open-market purchase (1,000 shares at $0.60) and a planned sale (1,000 shares at $28.00) executed under a Rule 10b5-1 plan. The director also holds a fully vested option with a $0.60 exercise price covering 1,000 shares and reports 125,077 shares beneficially owned after the transactions. From a capital-markets perspective, these trades are consistent with pre-established plan activity rather than opportunistic trading, and the absolute sizes reported are limited to 1,000-share lots, which appear immaterial relative to total outstanding shares (outstanding share count not provided in this filing).

Corporate Governance Expert

TL;DR: Use of a 10b5-1 plan and a signed Form 4 indicate compliance with insider trading rules.

The report states the sale was effected pursuant to a Rule 10b5-1 trading plan adopted September 6, 2024, and the Form 4 is signed by an attorney-in-fact, suggesting procedural adherence. The filing notes the director�s option was fully vested at the time of reporting. No departures, grants beyond the option noted, or other governance events are disclosed. The disclosure is narrowly focused on these transactions and does not raise governance red flags based on the information presented.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POST LEONARD E

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

400 SPECTRUM CENTER DRIVE, SUITE 2040

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		M		1,000	A	$0.6	1,000	D
Common Stock	09/03/2025		S(1)		1,000	D	$28	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$0.6	09/03/2025		M			1,000	(2)	07/08/2028	Common Stock	1,000	$0	125,077	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024.

2. Fully vested

	/s/ Joshua F. Patterson, Attorney-in-Fact for Leonard Post	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Leonard E. Post report on the Form 4 for CGON?

The filing reports a purchase of 1,000 common shares at $0.60 and a sale of 1,000 common shares at $28.00, both dated 09/03/2025.

Was the sale by the director part of a pre-arranged plan?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2024.

How many shares does Leonard E. Post beneficially own after these transactions?

The Form 4 reports 125,077 shares beneficially owned following the reported transactions.

Does the director have any stock options disclosed on this Form 4?

Yes. The director holds a director stock option exercisable at $0.60 for 1,000 shares, fully vested, with an expiration date shown as 07/08/2028.

Who signed the Form 4 filing for the reporting person?

The Form 4 is signed by Joshua F. Patterson, Attorney-in-Fact for Leonard Post on 09/04/2025.